关于我们About Us

南京澄实生物医药科技有限公司（TheraRNA Bio）成立于2020年，是一家以AI驱动mRNA药物研发为核心的国家高新技术企业，总部位于南京江北新区生物药谷。公司聚焦肿瘤治疗性疫苗、耐药菌感染mRNA药物和动物健康三大赛道，建立了从AI新生抗原预测、mRNA序列优化、LNP递送系统、GMP工艺到冻干制剂的全链条自主研发体系。

Nanjing TheraRNA Biomedical Technology Co., Ltd. was founded in 2020 as a National High-Tech Enterprise headquartered in Nanjing Jiangbei New Area Bio-Pharmaceutical Valley. The company focuses on three major therapeutic areas: personalized cancer vaccines, mRNA drugs for drug-resistant bacterial infections, and animal health.

公司是国内极少数同时拥有AI抗原预测算法、mRNA药物开发和LNP递送系统三项核心能力的企业。在肿瘤治疗领域，个性化肿瘤mRNA疫苗已联合多家三甲医院完成IIT临床研究，疾病控制率（DCR）100%、客观缓解率（ORR）71.4%。在耐药菌领域，公司全球首创耐药细菌mRNA疫苗管线，覆盖6种重要致病菌。

TheraRNA is one of the few companies in China with integrated capabilities in AI antigen prediction, mRNA drug development, and LNP delivery. In oncology, personalized mRNA cancer vaccines achieved DCR 100% and ORR 71.4%. In anti-bacterial therapeutics, the company pioneered the world's first mRNA vaccine pipeline targeting drug-resistant bacteria.

2025年，公司获批国家科技重大专项（疟疾mRNA疫苗），标志着mRNA平台能力获得国家级认可。

In 2025, the company was awarded a National Key S&T Program grant for its malaria mRNA vaccine.